Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | ESRRG | P62508 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PRF1 | P14222 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | WRN | Q14191 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764241 | 0.82 | HSD17B1 (0.72) | HSD17B1HSD17B2KDM4ECNR1ESRRG | |
| SCHEMBL14817162 | 0.82 | HSD17B1 (0.47) | HSD17B1HSD17B2KDM4ECNR1MAPT | |
| SCHEMBL147294 | 0.80 | HSD17B1 (0.49) | HSD17B1HSD17B2KDM4ECNR1ACHE | |
| SCHEMBL144559 | 0.79 | NPC1 (0.49) | HSD17B1HSD17B2KDM4EESRRGJAK2 | |
| SCHEMBL147151 | 0.79 | HSD17B1 (0.48) | HSD17B1HSD17B2KDM4ECNR1MEN1 | |
| SCHEMBL23555791 | 0.78 | HSD17B1 (0.50) | HSD17B1HSD17B2KDM4ECNR1MEN1 | |
| SCHEMBL13140798 | 0.78 | ALDH1A1 (0.50) | KDM4EJAK2PRF1MEN1MAPT | |
| SCHEMBL20557695 | 0.77 | MAP4K4 (0.50) | HSD17B1HSD17B2KDM4ECNR1ESRRG | |
| SCHEMBL14332594 | 0.77 | HSD17B1 (0.61) | HSD17B1HSD17B2KDM4ECNR1ESRRG | |
| SCHEMBL147152 | 0.77 | CNR1 (0.55) | HSD17B1HSD17B2CNR1JAK2PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885KDM4E 2616/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885KDM4E 2616/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885KDM4E 2616/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885KDM4E 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.